Author Affiliations: Dr Lauer is Contributing Editor and Dr Fontanarosa is Executive Deputy Editor, JAMA.
During the past decade, there has been tremendous progress in identifying
novel risk factors and precisely delineating the role of traditional risk
factors associated with coronary heart disease (CHD), with substantial research
advances related to the role of lipoproteins and lipid metabolism. Observational
studies have established the relationship of serum cholesterol and other lipoproteins
with CHD in specific subgroups.1- 3
Clinical trials have demonstrated convincing benefits of cholesterol lowering
for reducing death and myocardial infarction among patients with CHD4,5 as well as beneficial effects of cholesterol
lowering for decreasing the incidence of cardiac events in patients without
established coronary disease.6,7
Accurately synthesizing and appropriately applying this rapidly accumulating
evidence into clinical practice is essential for reducing the morbidity and
mortality associated with coronary disease.
Lauer MS, Fontanarosa PB. Updated Guidelines for Cholesterol Management. JAMA. 2001;285(19):2508-2509. doi:10.1001/jama.285.19.2508